stockportfolio.pro
Stocks / SMMT vs TECH
SMMT vs TECH: Which Stock Is the Better Buy?
Summit Therapeutics Inc. and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
TECH is the larger company ($11.0B vs $10.4B). On the fundamentals, TECH has the stronger return on equity (3.8% vs -163.9%). On the filings, SMMT carries fewer potential red flags (0 vs 1). Full numbers below — the stronger figure on each row is in green.
AI verdict — SMMT vs TECH, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Summit Therapeutics Inc. (SMMT) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $10.4B | $11.0B |
| Revenue (latest FY) | $0 | $1.22B |
| Net income (latest FY) | $-1.08B | $73.40M |
| Revenue growth (5y CAGR) | — | 10.5% |
| Net margin | — | 6.0% |
| Return on equity | -163.9% | 3.8% |
| P/E ratio | — | 101.2 |
| Dividend yield | — | 0.4% |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | No | Yes |
Compare with another company:
See the full SMMT vs TECH breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open SMMT's full financials → Open TECH's full financials →More comparisons
Frequently asked questions
Which is bigger, SMMT or TECH?
Bio-Techne Corporation is larger by market capitalization — $11.0B versus $10.4B.
Which grows faster, SMMT or TECH?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.